Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950718 | 1.00 | HSD17B10 (0.52) | HSD17B10AHRNFE2L2PPARGCYP1A2 | |
| SCHEMBL4617952 | 0.80 | CYP1A2 (0.52) | HSD17B10AHRNFE2L2PPARGCYP1A2 | |
| SCHEMBL1323496 | 0.80 | PTGES2 (0.51) | HSD17B10AHRNFE2L2PPARGCYP1A2 | |
| SCHEMBL2130148 | 0.80 | NFE2L2 (0.53) | HSD17B10AHRNFE2L2PPARGCYP1A2 | |
| SCHEMBL28850002 | 0.80 | AHR (0.50) | HSD17B10AHRNFE2L2PPARGCYP1A2 | |
| SCHEMBL28849952 | 0.80 | AHR (0.50) | HSD17B10AHRNFE2L2PPARGCYP1A2 | |
| SCHEMBL1323499 | 0.80 | PTGES2 (0.51) | HSD17B10AHRNFE2L2PPARGCYP1A2 | |
| SCHEMBL2130152 | 0.80 | NFE2L2 (0.53) | HSD17B10AHRNFE2L2PPARGCYP1A2 | |
| SCHEMBL4617948 | 0.80 | CYP1A2 (0.52) | HSD17B10AHRNFE2L2PPARGCYP1A2 | |
| SCHEMBL5729623 | 0.80 | CYP2A6 (0.50) | NFE2L2PPARGFBP1PTGES2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466906-A | Oridonin derivative, preparation method thereof, pharmaceutical composition and application | 中国人民解放军海军军医大学 | 2024-01-30 | — | — | CN | disclosed |
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | disclosed |
| EP-1379508-B9 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| EP-2234993-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| EP-1379508-B1 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009082347-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| EP-0031954-B1 | SULPHONAMIDES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1984-03-14 | — | — | EP | disclosed |
| EP-0031954-A2 | Sulphonamides, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1981-07-15 | — | — | EP | disclosed |
| EP-0004011-B1 | PHENOXYALKYLCARBOXYLIC-ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1981-04-01 | — | — | EP | disclosed |
| US-4259482-A | NON-SPECIFIC DEPRESSION OF CENTRAL NERVOUS SYSTEM | MEAD JOHNSON & COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4258058-A | Phenoxyalkylcarboxylic acid compounds and thrombocyte-aggregation inhibition | BOEHRINGER MANNHEIM GMBH (DE) | 1981-03-24 | — | — | US | disclosed |
| US-4206142-A | REACTING A STYRYLSULFONYLAMIDINE WITH A BASE | MEAD JOHNSON & COMPANY (US) | 1980-06-03 | — | — | US | disclosed |
| EP-0004011-A1 | Phenoxyalkylcarboxylic-acid derivatives, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1979-09-19 | — | — | EP | disclosed |
| US-4130663-A | ANTITHROMBOGENIC, ANTIHYPERTENSIVE | MEAD JOHNSON & COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
| US-4096183-A | Styrylsulfonylamidines | MEAD JOHNSON & COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4052455-A | ANALGESICS, BLOOD PLATELET AGGREGATION INHIBITORS | MEAD JOHNSON & COMPANY (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | PTGER1, SULT2A1, SULT1E1 | HSD17B10 458/4885AHR 1102/4885NFE2L2 717/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | HSD17B10 888/4885AHR 16/4885NFE2L2 1160/4885 |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | PTGER1, SULT2A1, SULT1E1 | HSD17B10 541/4885AHR 1140/4885NFE2L2 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.